---
title: "Galectin Therapeutics to file Phase 3 belapectin protocol in Q3 2026 for MASH cirrhosis, portal hypertension"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290558546.md"
description: "Galectin Therapeutics has aligned with the FDA via a Type C meeting to advance belapectin into a Phase 3 trial for MASH cirrhosis with portal hypertension. The company plans to submit the protocol in Q3 2026, targeting disease progression prevention using blinded central endoscopy reviews. Galectin is currently seeking strategic or financial partners to fund the development and commercialization of the drug."
datetime: "2026-06-23T11:51:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290558546.md)
  - [en](https://longbridge.com/en/news/290558546.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290558546.md)
---

# Galectin Therapeutics to file Phase 3 belapectin protocol in Q3 2026 for MASH cirrhosis, portal hypertension

-   Galectin Therapeutics reported FDA Type C meeting alignment to advance belapectin into a Phase 3 trial for MASH cirrhosis with portal hypertension. \* No new clinical results were presented; the update outlines a future registration-focused study intended to support a full approval filing. \* The planned trial targets prevention of disease progression, using a composite clinical outcome that includes avoiding development of large esophageal varices. \* FDA accepted the blinded central endoscopy review approach, supporting consistency of key assessments across sites. \* Protocol submission is planned for Q3 2026; the company is pursuing strategic or financial partners to fund development and commercialization. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-026031), on June 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [GALT.US](https://longbridge.com/en/quote/GALT.US.md)

## Related News & Research

- [Galectin Therapeutics posts corporate presentation highlighting belapectin program for MASH cirrhosis, portal hypertension](https://longbridge.com/en/news/292638312.md)
- [Cereno Scientific activates first site for Phase IIb EPIMODE trial of CS1 in pulmonary arterial hypertension](https://longbridge.com/en/news/295750138.md)
- [Can-Fite says Phase III namodenoson trial in advanced liver cancer advances under FDA, EMA guidance](https://longbridge.com/en/news/295654944.md)
- [Driveitaway delays Q2 10-Q filing, cites need for more time to compile and review disclosures](https://longbridge.com/en/news/295972176.md)
- [Charlie's Holdings delays Q2 Form 10-Q filing, cites extra time for disclosure review](https://longbridge.com/en/news/295979005.md)